ClinicalTrials.gg
RecruitingNCT07585409ActivPARKUpdated May 15, 2026

Physical Activity in Persons With Parkinson's Disease

An observational study in PARKINSON DISEASE (Disorder), Physical Activity and Sedentary Behaviors, sponsored by Karolinska Institutet. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by Karolinska Institutet · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Karolinska Institutet.

Started
2026
the only one that year
Observational
4 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Parkinson Disease by Karolinska Institutet, this one is the only one that started in 2026, is one of 4 observational ones, and was the 9th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 10 studies in Parkinson Disease by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Karolinska Institutet, or all of them as a file.
02

Study summary

This project aims to identify why some people with Parkinson's disease (PwPD) become less physically active, and which factors support or hinder activity. Understanding these factors is essential for developing person centred interventions and effective support that can be implemented in routine healthcare. A national, multicentre longitudinal cohort study will be conducted including approx 450 PwPD from five Swedish regions (including the internal pilot NCT06901869). Physical activity will be measured objectively with activity monitors, combined with clinical assessments and digital questionnaires over four years. The primary outcome is physical activity level (accelerometer measured decline), and exposure variables include physical, cognitive, disease specific, social, environmental, motivational, and personal factors. Data collection involves clinical tests, questionnaires, accelerometer data, and patient reported experiences.

This is a continuation of an internal pilot study NCT06901869. The study will enable early identification of those at risk for declining activity and guide development of person centred, evidence based interventions. Long term, it aims to integrate activity monitoring and risk factor screening into routine care to improve health and quality of life for PwPD.

03

Conditions studied

  • PARKINSON DISEASE (Disorder)
  • Physical Activity
  • Sedentary Behaviors

Keywords

  • Parkinson's disease
  • Physical activity
  • activity monitors
  • accelerometers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

People with Parkinson's disease with mild to severe severity (Hoehn \& Yahr 1-4) of all ages

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People diagnosed with idiopathic Parkinson's disease
  • Hoehn \& Yahr 1 to 4

Exclusion criteria

Exclusion Criteria:

  • Hoehn \& Yahr 5 (i.e. wheelchair bound or bedridden unless aided)
  • Unable to perform critical physical activity and clinical assessments
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • People with Parkinson´'s disease

    No intervention

06

What researchers measure

Primary outcomes

  1. Physical activity - low and moderate intensity

    The primary outcome is changes over time in PA (i.e. low + moderate-vigorous intensity PA in time spent per day) measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

Secondary outcomes

  1. Physical activity - total vector magnitude

    The secondary outcomes are change over time in total vector magnitude measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

  2. Physical activity - low intensity

    The secondary outcomes are change in time spent in low intensity physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

  3. Physical activity - moderate high intensity

    The secondary outcomes are change in time spent in moderate-vigorous physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

  4. Physical activity- sedentary

    The secondary outcomes are change in sedentary time per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

  5. Physical activity - steps

    The secondary outcomes are change in steps per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.

    Time frame: Baseline and yearly follow-ups for 3 years

Other outcomes

  1. Disease severity, Parkinsons symptoms

    Disease severity measured with the Movement Disorders Society -Unified Parkinson's Disease Rating Scale) parts 1 to 4. Higher scores = worse/more symptoms

    Time frame: Baseline and 3 year follow-up

  2. Gait

    Gait speed in m/s measured with the 10 meter walking test or through gait analysis.

    Time frame: Baseline and 3 year follow-up

  3. Balance performance

    Assessed with the Mini-BESTest. Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. 0-28 points with higher scores indicating better balance control

    Time frame: Baseline and 3 year follow-up

  4. Anxiety and depression

    Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better

    Time frame: Baseline and yearly follow-ups for 3 years

  5. Cognitive performance

    Assessed with the Montreal Cognitive Assessment (MoCA), 0-25, higher score = better

    Time frame: Baseline and 3 year follow-up

  6. Motivation

    Assessed with the Behavioural Regulation in Exercise Questionnaire (BREQ 4), a 28-item survey that measures exercise motivation. The questionnaire uses a 7-point Likert scale, ranging from one to seven. Maximum 196. Higher scores = higher motivation

    Time frame: Baseline and yearly follow-ups for 3 years

  7. Self-efficacy

    Assessed with the Self-efficacy and motivation for exercise/physical activity (ESES). 10 questions rated on a 4 point Likert scale. Maximun 40 points, higher scores= better self-efficacy

    Time frame: Baseline and yearly follow-ups for 3 years

  8. Physical activity history and preferences,

    Self-made questions on physical activity history and preferences

    Time frame: Baseline

  9. Self assessed cognitive function

    Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse

    Time frame: Baseline and yearly follow-ups for 3 years

  10. Non-Motor Symptoms

    Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer. More yes answers = more non-motor symptoms

    Time frame: Baseline and yearly follow-ups for 3 years

  11. Walking ability- self rated

    WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)

    Time frame: Baseline and yearly follow-ups for 3 years

  12. Freezing of gait - self-assessed

    Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)

    Time frame: Baseline and 3 year follow-up

  13. Balance confidence

    Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better

    Time frame: Baseline and yearly follow-ups for 3 years

  14. Fatigue

    Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree . more points/score= worse.

    Time frame: Baseline and yearly follow-ups for 3 years

  15. Disability

    World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse

    Time frame: Baseline and 3 year follow-up

  16. Sleep

    Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions. Higher= worse

    Time frame: Baseline and 3 year follow-up

  17. Self-rated pain

    Assessed with visual analog scale, VAS from 0 to 100

    Time frame: Baseline and yearly follow-ups for 3 years

  18. Health related quality of life

    Parkinson's Disease Questionnaire (PDQ39). The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communications and bodily discomfort). The sum score is as a percentage score ranging between 0 and 100. Higher is better

    Time frame: Baseline and yearly follow-ups for 3 years

  19. Wellbeing

    The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better

    Time frame: Baseline and yearly follow-ups for 3 years

  20. Nutrition

    Mini Nutritional Assessment, max 14. higher = better

    Time frame: Baseline and 3 year follow-up

  21. Socioeconomic status

    Education and income level.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.

Supporting information: Statistical analysis plan

Time frame: We plan to share this when applicable on OSF or similar

Access criteria: The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2030, 59 months after the start.

Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 59 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
May 13, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Jan 30, 2031
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585409
Responsible party
Erika Franzén (Professor, Karolinska Institutet) — Principal investigator
First posted
May 13, 2026
Start date
Jan 15, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Jan 30, 2031 (estimated)
Last update
May 15, 2026

Study contacts

Compliance Office Karolinska Insitutet
Contact
compliance@ki.se
+46852480000
Erika Franzén
Contact
erika.franzen@ki.se
+46852488878
Erika Franzén
principal investigator · Karolinska Institutet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion